How and Under What Conditions Do Patient Portals Improve Cancer Screening Completion: A Scoping Review.

Problem-solving tools to encourage cancer screening among low health literacy populations in Western New York.

People with HIV have a higher incidence and mortality from screenable cancers than the general population. Among women, the 4 most common cancers are breast, colorectal, lung, and cervical cancers. This study examined breast, colorectal, lung, and cervical cancer screening rates among Black women with HIV and disparities that exist by immigration status. With a sample of 604 women, we examined cancer screening rates for breast, colorectal, lung, and cervical cancers and examined the rates by country of origin. Generalized linear mixed models were used to examine potential factors affecting these rates and the odds of screening by country of origin: US-born women (USBW) and non-US-born women (NUSBW). Cancer screening rates were low for all cancer categories for both groups. A screening rate of 48.7% was estimated for breast cancer (NUSBW-35.9% versus USBW-50.4%), 6.3% for lung cancer, 25.5% for colorectal cancer, and 72.8% for cervical cancer. NUSBW had lower screening rates for all 4 cancers compared with USBW. Possible predictors for cancer screenings were years of living with HIV [odds ratios (OR) 1.11; 95% CI: 1.07 to 1.14] and no viral suppression (OR 0.34; 95% CI: 0.15 to 0.76). Black women with HIV and much more immigrant subgroups may face additional barriers to accessing required cancer screening services in addition to being disproportionately affected by HIV. This emphasizes the urgent need for tailored, culturally relevant outreach and education to enhance cancer screening.

Evaluation of culturally tailored breast cancer education video in a primarily Hispanic population.

Impact of Self-Reported Patient-Provider Communication on the Use of High- and Low-Value Care Among U.S. Adults.

Survey on changes in colorectal cancer screening participation at Minamisoma city after the Great East Japan earthquake using clustering analysis.

Trends in cancer incidence among people with human immunodeficiency virus in South Korea: a nationwide National Health Insurance Service data-based study.

Cancer care disruptions among vulnerable populations during the COVID-19 pandemic: A scoping review.

Community engagement and empowerment to address health inequalities: A rapid evidence review.

False-positive iFOBT in colorectal cancer screening: Association with prescription drug use in The Malaysian Cohort.

Rural barriers to colonoscopy screening identified through patient navigation.

Blood-based circulating tumour DNA (ctDNA) tests for colorectal cancer screening: Systematic review and meta-analysis of diagnostic accuracy.

Characteristics and Effectiveness of Patient Navigation Programs on Colorectal Cancer Screening and Follow-Up Colonoscopy Uptake: A Systematic Review.

Autoimmune myelitis represents a heterogeneous group of disorders whose classification has evolved substantially over the past decade. Advances in antibody diagnostics and the widespread use of immune checkpoint inhibitors (ICIs) in oncology have reshaped current concepts, revealing mechanistic and clinical overlaps between antibody-mediated, paraneoplastic, and treatment-induced myelopathies. Antibody-associated myelitis, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), aquaporin-4 (AQP4)-immunoglobulin G (IgG)-positive NMOSD and glial fibrillary acidic protein (GFAP) astrocytopathies, accounts for many cases previously labeled idiopathic. Paraneoplastic myelitis is rare but severe, possibly overlapping with NMOSD or GFAP astrocytopathies. In parallel, ICIs have emerged as a novel trigger of immune-mediated myelitis, capable of inducing de novo inflammatory spinal cord syndromes or unmasking latent autoimmune diseases, including AQP4-IgG-positive NMOSD and GFAP astrocytopathies but not MOGAD. Autoimmune myelitis is best conceptualized within an etiological and context-dependent framework integrating antibody status, oncological evaluation, and exposure to immunotherapies. The expanding interface between astrocytopathies, paraneoplastic syndromes, and ICI-associated myelitis has important diagnostic and therapeutic implications, underscoring the need for systematic antibody testing and cancer screening in patients with inflammatory myelopathy.

Economic benefit of expanding mammography screening for breast cancer in Colombia: A cost modelling analysis.

Systematic skin cancer screening in patients treated with biologics for chronic inflammatory rheumatic diseases: an 11-year experience.

Psychosocial outcomes of low-dose computed tomography screening for lung cancer in high-risk populations: A systematic review update.

Institutional practices for cancer: Comparison of social and health care along disease trajectory in five countries with high survival rates.

Methylated Septin9 as an auxiliary biomarker for the diagnostic, recurrence monitoring and prognosis of colorectal cancer.

Mycoplasma genitalium infection and pelvic inflammatory disease: A 12-month prospective study in Japanese women.